Related Experiment Video
Updated: Feb 16, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Atorvastatin prevents postoperative atrial fibrillation in patients undergoing cardiac surgery
Insights
Statin therapy, particularly atorvastatin, significantly reduces the risk of postoperative atrial fibrillation (AF) after cardiac surgery. Moderate doses appear most effective, especially for patients undergoing coronary artery bypass grafting (CABG).
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Observational studies suggest statins may reduce postoperative atrial fibrillation (AF) in cardiac surgery patients.
- Retrospective studies have yielded conflicting results regarding statin efficacy for AF prevention.
- The study aimed to clarify the impact of different statins and doses on postoperative AF risk.
Purpose of the Study:
- To evaluate the effectiveness of various statins in reducing the risk of postoperative atrial fibrillation (AF).
- To determine if different statin dosages influence the prevention of AF after cardiac surgery.
- To analyze the impact of statin therapy on AF in patients undergoing specific procedures like coronary artery bypass grafting (CABG).
Main Methods:
- A systematic search of PubMed, EMBASE, and Cochrane Database for randomized controlled trials (RCTs) up to June 2016.
- Inclusion of 18 RCTs involving 4003 statin-naive patients undergoing cardiac surgery.
- Application of a random-effects model to address heterogeneity in study results.
Main Results:
- Overall statin therapy significantly decreased the risk of AF (RR: 0.57, 95% CI: 0.45-0.73).
- Atorvastatin demonstrated a significant reduction in new-onset AF risk (RR: 0.53, 95% CI: 0.41-0.69).
- Moderate-dose statin therapy appeared optimal (RR: 0.42, 95% CI: 0.28-0.64), with benefits noted in CABG patients (RR: 0.52, 95% CI: 0.39-0.68).
Conclusions:
- Statin therapy offers a protective effect against postoperative AF.
- Atorvastatin, particularly at moderate doses, is associated with a reduced risk of new-onset AF in post-CABG patients.
- Simvastatin may help prevent AF recurrence; further prospective studies are recommended.
Background:
Observational studies have suggested that statins might reduce postoperative atrial fibrillation (AF) in patients undergoing cardiac surgery. However, a number of retrospective studies have shown equivocal results. We aimed to evaluate whether different statins can reduce the risk for AF at different doses.
Methods:
We searched PubMed, EMBASE, and the Cochrane Database for all published randomized controlled trials (RCTs) that examined the effects of statin therapy on AF up to June 2016. A random-effects model was used when there was substantial heterogeneity.
Results:
Eighteen published studies that included 4003 statin-naive patients (2009 receiving satins and 1994 receiving regime) with sinus rhythm before cardiac surgeries were identified for inclusion in the analysis. Thirteen studies investigated the prevention of AF by atorvastatin, two studies investigated the prevention of AF by rosuvastatin, two studies investigated the prevention of AF by simvastatin, and one study investigated the prevention of AF by pravastatin. The remaining two studies compared the effects of different doses of atorvastatin on the prevention of AF in patients undergoing coronary artery bypass grafting (CABG). Overall, statin therapy was associated with a significant decrease in the risk for AF (relative risk [RR]: 0.57, 95% confidence interval [CI]: 0.45-0.73, P = 0.000). However, subgroup analyses showed that only atorvastatin reduced the risk for new-onset AF in patients after cardiac surgery (RR: 0.53, 95% CI: 0.41-0.69, P = 0.000). Patients undergoing CABG possibly received more benefits from statin therapy (RR: 0.52, 95% CI: 0.39-0.68).Statin therapy in a moderate dose may be optimal (RR: 0.42, 95% CI: 0.28-0.64).
Conclusions:
This meta-analysis suggests that statin therapy has an overall protective effect against postoperative AF, among which atorvastatin in a moderate dose was significantly associated with a decreased risk for new-onset AF in patients after CABG. Moreover, simvastatin may also exert a significant protective effect against the AF recurrences in patients undergoing cardiac surgeries; hence, further prospective studies are warranted.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Cancer Prevention
Some...
Prevention of Further Absorption of Poison
Preventive Healthcare Services

